Sherin Dib, Rana Makhous
firstname.lastname@example.org , Rana.email@example.com
Sherin Dib1, Rana Makhous2
1Master Student in Pharmacology and Toxicology Department, Faculty of Pharmacy, Tishreen University. Lattakia, Syria.
2Doctor in Pharmacology and Toxicology Department, Faculty of Pharmacy, Tishreen University, Lattakia, Syria.
Volume - 13,
Issue - 5,
Year - 2020
Background and objective: Diabetes mellitus (DM) is a global pandemic. The increased Mean platelet volume (MPV) and its activity may play a role in the development of vascular complications of this metabolic disorder. Metformin, the first-line therapy for T2DM, the only drug demonstrated to reduce cardiovascular complications in diabetic patients. However, whether metformin can effectively prevent thrombosis and its potential mechanism of action is not fully understood. In this study, the first aim is to determine whether there is a difference in MPV between diabetics with and without macro- and microvascular complications,compared to nondiabetics. The second aim is to examine the effects of metformine on MPV values in newly diagnosed type 2 DM patients on metformin monotherapy, and to investigate whether a correlation exists between MPV and fasting blood glucose changes after and before treatment. Methods: MPV values were measured MPV in 87 newly diagnosed Type 2 diabetic patients, 25 insulin-dependent diabetic patients and 40 nondiabetic control subjects, who had complete blood count on venous blood sample taken into tripotassium EDTA, using automatic blood counter (Diagon D-Cell 60 CBC Eurup). The blood glucose level was measured by glucose oxidase method. Statistical evaluation was performed by SPSS for Windows statistics programme using linear regression analysis, Student's t, one way Anova, and Pearson correlation tests. Results: MPV values were significantly higher in Insulin- dependent T2DM group compared to the newly diagnosed T2DM and control [9.7 ± 0.78 FL vs 8.52 ± 0.8 FL and 8.48 ± 0.9 FL ( P=0)], respectively. Among the newly diagnosed patients MPV values showed a low positive correlation with patient age (R = 0.37, P= 0 ) but no correlation was with BMI ( R=-0.001 ? P=0.99 ) and initial fasting plasma glucose (P= 0.111, R=0.172 ). MPV values were significantly reduced after 6-month metformin therapy [8.56±0.78 vs 8.18±0.70 (P<0.05)]. There were no statistically significant associations of ?MPV with ?FBG levels (beta coefficient=0.41,P=0.51) after metformin treatment Conclusions: Our results showed that MPV values significantly higher in insulin- dependent T2DM patients than in the newly diagnosed T2DM patients and nondiabetic controls.The increased MPV may be due to the diabetic complication which increase with disease progression. Our results suggest that metformin had decreased MPV in diabetes mellitus Regardless of glucose lowering effect.These findings may provide a further explanation for the anti-atherogenic effect of metformin.
Cite this article:
Sherin Dib, Rana Makhous. The Effect of Metformin on Mean Platelet Volume. Research J. Pharm. and Tech 2020; 13(5): 2329-2334. doi: 10.5958/0974-360X.2020.00419.9
1. Cho, N., et al., IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 2018. 138: p. 271-281.
2. Tang, W.H., et al., Aldose Reductase–Mediated Phosphorylation of p53 Leads to Mitochondrial Dysfunction and Damage in Diabetic Platelets. Circulation, 2014. 129(15): p. 1598-1609.
3. Vazzana, N., et al., Diabetes mellitus and thrombosis. Thrombosis Research, 2012. 129(3): p. 371-377.
4. Xin, G., et al., Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release. Scientific Reports, 2016. 6: p. 36222.
5. Viles-Gonzalez, J.F., et al., Update in atherothrombotic disease. The Mount Sinai Journal of Medicine, New York, 2004. 71(3): p. 197-208.
6. Yuri Gasparyan, A., et al., Mean platelet volume: a link between thrombosis and inflammation? Current Pharmaceutical Design, 2011. 17(1): p. 47-58.
7. Papanas, N., et al., Mean platelet volume in patients with type 2 diabetes mellitus. Platelets, 2004. 15(8): p. 475-478.
8. Yngen, M., et al., Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diabetes and Vascular Disease Research, 2006. 3(1): p. 52-56.
9. Natarajan, A., A.G. Zaman, and S.M. Marshall, Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diabetes and Vascular Disease Research, 2008. 5(2): p. 138-144.
10. Angiolillo, D.J., Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care, 2009. 32(4): p. 531-540.
11. Martin, J., et al., The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thrombosis research, 1983. 32(5): p. 443-460.
12. Gin, H., et al., Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Research and Clinical Practice, 1989. 6(1): p. 61-67.
13. Association, A.D., 2. Classification and diagnosis of diabetes. Diabetes care, 2017. 40 (Supplement 1): p. S11-S24.
14. Demirtunc, R., et al., The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. Journal of Diabetes and its Complications, 2009. 23(2): p. 89-94.
15. Gerich, J.E., Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. Clinical cornerstone, 2007. 8(3): p. 53-68.
16. Fox, C.S., et al., Increasing cardiovascular disease burden due to diabetes mellitus. Circulation, 2007. 115(12): p. 1544-50.
17. Mitchell, R.N., Hemodynamic disorders, thromboembolic disease, and shock. Pathologic Basis of Diseases, 8th ed.; Kumar, V., Abbas, AK, Fausto, N., Aster, JC, Eds, 2005: p. 111-134.
18. Angiolillo, D.J., et al., Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes, 2005. 54(8): p. 2430-2435.
19. Bae, S.H., et al., Platelet activation in patients with diabetic retinopathy. Korean Journal of ophthalmology, 2003. 17(2): p. 140-144.
20. Hekimsoy, Z., et al., Mean platelet volume in Type 2 diabetic patients. Journal of Diabetes and its Complications, 2004. 18(3): p. 173-176.
21. Colwell, J.A. and R.W. Nesto, The platelet in diabetes: focus on prevention of ischemic events. Diabetes care, 2003. 26(7): p. 2181-2188.
22. Chang, H.A., et al., The Role of Mean Platelet Volume as a Predicting Factor of Asymptomatic Coronary Artery Disease. Korean Journal of Family Medicine, 2010. 31(8): p. 600-606.
23. Ateş, O., et al., Association of mean platelet volume with the degree of retinopathy in patients with diabetes mellitus. Eur J Gen Med, 2009. 6(2): p. 99-102.
24. Zuberi, B., N. Akhtar, and S. Afsar, Comparison of mean platelet volume in patients with diabetes mellitus, impaired fasting glucose and non-diabetic subjects. Singapore Medical Journal, 2008. 49(2): p. 114.
25. Kodiatte, T.A., et al., Mean platelet volume in type 2 diabetes mellitus. Journal of laboratory physicians, 2012. 4(1): p. 5.
26. Carr, M.E., Diabetes mellitus: a hypercoagulable state. Journal of Diabetes and its Complications, 2001. 15(1): p. 44-54.
27. Queen, L., et al., Nitric oxide generation mediated by β-adrenoceptors is impaired in platelets from patients with Type 2 diabetes mellitus. Diabetologia, 2003. 46(11): p. 1474-1482.
28. Tripathi, B.K. and A.K. Srivastava, Diabetes mellitus: Complications and therapeutics. Medical Science Monitor, 2006. 12 (7): p. RA130-RA147.
29. Thomas, N. and N. Kapoor, A Practical Guide to Diabetes Mellitus- 7th Edition. 2016.
30. Morohoshi, M., et al., Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes, 1996. 45(7): p. 954-959.
31. Guha, M., et al., Molecular mechanisms of tumor necrosis factor α gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and-independent pathways. Journal of Biological Chemistry, 2000. 275(23): p. 17728-17739.
32. Cosentino, F., et al., High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation, 2003. 107(7): p. 1017-1023.
33. Ceriello, A. and E. Motz, Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004. 24(5): p. 816-823.
34. Stratmann, B. and D. Tschoepe, Atherogenesis and atherothrombosis–focus on diabetes mellitus. Best Practice and Research Clinical Endocrinology and Metabolism, 2009. 23(3): p. 291-303.
35. Wang, R.-T., et al., Increased mean platelet volume is associated with arterial stiffness. Platelets, 2011. 22(6): p. 447-451.
36. Walker, B., et al., Davidson’s Principle and Practice of Medicine. 22nd. Edinburgh, Elsevier.
37. Sharpe, P. and T. Trinick, Mean platelet volume in diabetes mellitus. QJM: An International Journal of Medicine, 1993. 86(11): p. 739-742.
38. Dolasık, I., et al., The effect of metformin on mean platelet volume in dıabetıc patients. Platelets, 2013. 24(2): p. 118-121.
39. Formoso, G., et al., Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metabolism Research and Reviews, 2008. 24(3): p. 231-237.
40. Roussel, R., et al., Metformin use and mortality among patients with diabetes and atherothrombosis. Archives of Internal Medicine, 2010. 170(21): p. 1892-1899.